News 2019-08-29T10:18:44+00:00

PRESS RELEASE

August 29th, 2019

PRESS RELEASE: ADCendo accepted into the Creation House program of BioInnovation Institute (BII), securing a convertible loan of 10 million DKK

Download this press release:

ADCendo PR Aug29 2019

Copenhagen, Denmark – August 29th, 2019

ADCendo ApS, a spin-out from the University of Copenhagen and Rigshospitalet, announces having been accepted into the BioInnovation Institute (BII) Creation House program. As part of the program, ADCendo has secured a convertible loan of 10 million DKK for furthering its novel antibody-drug conjugates (ADCs) being developed for treatment of cancers.

In 2017, following publication of scientific proof-of-concept, ADCendo was established as a spin-out from the Finsen Laboratory of Rigshospitalet and the University of Copenhagen, with the purpose of developing a new type of targeted anti-cancer drug, in the form of antibody-drug conjugates (ADCs) directed at a novel target receptor, uPARAP. An approach that potentially enables targeted therapy in several cancer forms where expression of the target has been found to be highly upregulated, including soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme (GBM) and triple-negative breast cancer. Furthermore, recent research suggests that targeting uPARAP-positive stromal cells (healthy cells surrounding a solid tumor) with this approach, may potentially offer opportunities for treating several much more commonly occurring carcinomas, including breast, colon, pancreatic, prostate, ovarian and renal cancers.

CSO of ADCendo and group leader at The Finsen Laboratory, Niels Behrendt, explains: “Based on our early results obtained at the Finsen laboratory, we were granted a pre-seed grant from Novo Holdings enabling us to make significant improvements to the overall performance of our early ADC candidates. Our results have been very well received by our international ADC network, and with the expanded access to BII, as well as the additional financial support, we are looking forward to furthering the development of our clinical candidate. Having created the scientific basis of the company through many years of basic cancer research, we are of course very excited about this opportunity to take our results further towards clinical utilization, and we are very proud of having been selected for the Creation House program at BII”.

Commenting on the ADCendo spin-out, Bo Porse, head of the Finsen Laboratory, notes: “At the Finsen Laboratory, we have a strong focus on the translational aspects, in addition to our basic research. The successful path of ADCendo from basic cancer research by its founders at the Finsen Laboratory, to a spin-out biotech, nicely illustrates how our research strategy may contribute to development of novel, innovative anti-cancer treatments”.

ADCendo is, in parallel with furthering its ADCs, preparing pre-clinical and clinical development plans for metastatic soft tissue sarcoma (STS), a serious disease where patients have a median survival of only 12-18 months. Importantly, ADCendo aims to fill the gap following the drug Lartruvo (Olaratumab, an anti-PDGFR-α antibody), which was withdrawn from the STS market in early 2019 following a failed confirmatory phase III study. At launch, Lartruvo was the first new drug to be approved for first-line treatment of STS in 40 years, and the drug was well received and hoped to provide treatment for STS patients with substantial unmet needs. Going forward, ADCendo aims at developing its ADC strategy for STS, based on a development track similar to Lartruvo, which was granted orphan designation, fast track, breakthrough therapy designation, priority review status, and accelerated approval for STS, enabling a faster and more cost-effective clinical development path.

Henrik Stage, CEO of ADCendo explains: “In short, ADCendo’s business strategy is aimed at moving its lead compound into the clinic for STS patients, preferably based on an orphan drug designation, and hopefully receiving conditional approval for the drug to fill the gap after Lartruvo. Having been accepted for the BII program and receiving the convertible loan funding is an important step towards maturing the company, and preparing for the additional investments needed from investors and partners, to enable us to fulfil our ambitions of bringing our novel ADC drug to the market for treatment of patients with an unmet medical need”.

Commenting on ADCendo’s acceptance for the BII program, Hervør Lykke Olsen, Senior Scientific Business Developer at BioInnovation Institute, says: “The goal for ADCendo is to develop a new drug for soft tissue sarcoma (STS), which is a heterogenous groups of tumors notorious for their recurrence, overall complexity, and difficulty to treat. Research from the ADCendo team has shown that the novel target, uPARAP, is highly overexpressed on the surface of cancer cells of STS tumors, making it very well suited for targeting with ADCendo’s ADCs. BII’s support on funding and business development can boost ADCendo to succeed in commercialization of the treatment to benefit patients”.


About ADCendo ApS

ADCendo ApS is a biotech company developing novel antibody-drug conjugates (ADCs) for treatment of certain cancers forms, for which there today are no effective treatments available for patients with late stage disease. The company was founded in 2017 by scientists Niels Behrendt, Lars Henning Engelholm and Christoffer Nielsen from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen, and Henrik Stage, a biotech-entrepreneur active in several biotech companies, and previously CEO/CFO of Santaris Pharma which was acquired by Roche in 2014. The team was in 2017 joined by Andreas Hald, an experienced scientist with a background from both basic research and the pharma industry.

ADCendo holds the worldwide rights to explore, and an option to acquire, certain inventions made by the founders and patented by the University of Copenhagen and Rigshospitalet. Proof-of-concept for the drug modality pursued by ADCendo has been published by the scientific founders.

ADCendo is a Creation House company at BioInnovation Institute (BII), a Novo Nordisk Foundation initiative.

For more information: www.adcendo.dk

About antibody-drug conjugates (ADCs)

ADCendo’s first drug candidate is an ADC that is directed against a receptor with molecular properties that are unique in an ADC context, allowing for extremely efficient ADC drug processing, and is based on a species cross-reactive antibody enabling an attractive position for early tox and development purposes. The receptor has been found to be highly expressed in several cancers including sarcomas (soft-tissue sarcoma and osteosarcoma) and glioblastomas (GBM; the most malignant brain tumors), which are all indications with a significant unmet treatment need.

ADCs are a new class of highly potent biopharmaceutical drug composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. ADCs combine the unique and very sensitive targeting capabilities of antibodies, with the potent effects of the conjugated cytotoxic drugs, allowing sensitive discrimination between healthy and cancer tissues.

To date, five ADCs have received market approval, and at least 80 unique ADCs are currently in clinical trials.

About BioInnovation Institute

BioInnovation Institute is an international initiative for research-based innovation and entrepreneurship, embracing every phase of a life-science start-up. BII, located in Copenhagen, Denmark, offers start-ups within medtech, biotech and pharma 2300 square-meters of state-of-the art lab and office facilities, business acceleration programs, start-up business incubation, commercial support, unique funding opportunities and access to high-level mentoring and international networks. BII is an initiative of the Novo Nordisk Foundation.

Read more on www.bioinnovationinstitute.com

About the Finsen Laboratory

The Finsen Laboratory is a basic cancer research department of Rigshospitalet, also affiliated with the University of Copenhagen as a part of Biotech Research and Innovation Centre (BRIC). Focus areas are elucidation of the mechanisms of cancer initiation, maintenance and metastasis, with the aim to identify biomarkers and novel targets for therapeutic intervention. The laboratory houses six research groups and is situated at Copenhagen Biocenter close to Rigshospitalet and academic institutions.

For more information: www.finsenlab.dk

About the University of Copenhagen / Capital Region of Denmark

The Tech Transfer Office at the University of Copenhagen helps commercialize the excellent research conducted at the University of Copenhagen and the hospitals of the Capital Region of Denmark. The Tech Transfer Offices commercial officers identify research with commercial potential and helps to realize that potential by license agreements with existing businesses or start-up businesses (spin-outs). The University of Copenhagen is ranked 35th in Reuters’ list of Europe’s Most Innovative Universities (2019).

For more information: business.ku.dk/commercialisation

For further information, please contact: Henrik Stage, CEO of ADCendo ApS
+45 4026 0900
henrik.stage.dk (at) gmail.com

From left to right: Christoffer Nielsen, Niels Behrendt, Henrik Stage and Lars Engelholm. Not pictured is team member Andreas Hald.

Jan 14th, 2019

ADCendo receives investment from Innovation Fund Denmark

ADCendo has secured additional soft funding through an Innobooster investment from Innovation Fund Denmark.

This enables initiation of key activities with international partners, including testing of ADCs carrying state-of-the-art payloads in combination with ADCendo’s humanized antibodies, in order to move further towards a clinical lead candidate ADC.

The ADCendo team is grateful to Innovation Fund Denmark for the recognition.

May 16th, 2018

ADCendo invited to present at BioEquity Europe in Ghent

Copenhagen, Denmark – May 16th, 2018

CEO to present the company in Pre-seed Showcase

ADCendo ApS announce that Henrik Stage, Chief Executive Officer of ADCendo, will present the company at the Pre-seed Showcase at BioEquity Europe in Ghent on May 16th 2018.

“We are very happy to be invited to present the company at BioEquity Europe, where we will get in front of some of the leading figures within Europe’s pharmaceutical and biotech industry, and present our current plans going forward, based on recent scientific progress on development of optimal ADCs directed against our target”, says Henrik Stage, CEO of ADCendo.


About ADCendo ApS

ADCendo ApS is a biotech company researching and developing novel antibody-drug-conjugates (ADCs) against selected serious bone, connective tissue and brain cancers for which there today are no treatments available. The company was founded in 2017 by the scientist inventors, Niels Behrendt, Lars Henning Engelholm and Christoffer Nielsen, from The University of Copenhagen / Rigshospitalet and Henrik Stage, a biotech-entrepreneur active in several biotech companies and previously CEO/CFO of Santaris Pharma which was acquired by Roche in 2014. ADCendo holds the worldwide rights to explore certain inventions made by the founders and patented by the University of Copenhagen and Rigshospitalet as well as results from ongoing research – partly financed through a pre-seed grant from Novo Seeds. Research made by the scientific founders and based on ADCendo’s drug candidates was published in the peer-reviewed journal Oncotarget in 2017.

ADCendo has secured funding for its early preclinical activities related to lead compound selection, pharmacology and preliminary tox studies and will initiate discussions with potential investors regarding the funding needed for scaling up, IND enabling tox and preparation for and making phase 1/2 studies. Further the company will continue discussions with pharma companies to explore potential collaboration opportunities for its projects. For more information: www.adcendo.dk.


ADCs
are a new class of highly potent biopharmaceutical drug composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound.

ADCs combine the unique and very sensitive targeting capabilities of antibodies allowing sensitive discrimination between healthy and cancer tissues with the cell-killing ability of cytotoxic drugs.

To date, four ADCs have received market approval and several ADCs are currently in clinical trials. ADCendo’s first drug candidate is an ADC targeting the uPARAP receptor. This receptor is highly expressed in several bone, connective tissue and brain cancers such as:

  • Sarcomas (primary bone cancer and soft tissue tumors with no efficient present treatment if metastasis has occurred)
  • Glioblastomas (GBM; the most malignant brain tumors and presently incurable)

For further information please contact:
Henrik Stage, CEO of ADCendo ApS

+45 4026 0900
henrik.stage.dk (at) gmail.com

PRESS RELEASE

November 3rd, 2017

PRESS RELEASE: New license agreement sets course for development of cancer drugs with targeting ability

Download this press release here:

ADCendo Press Release 03.11.2017

Copenhagen, Denmark – November 3rd, 2017

A worldwide license agreement with the University of Copenhagen and Capital Region of Denmark sets spin-out biotech company ADCendo on track to develop novel treatments for selected bone, connective tissue and brain cancers with the targeting capabilities of antibodies

ADCendo ApS, the University of Copenhagen and the Capital Region of Denmark have entered a license agreement with the aim of developing novel, targeted cancer treatments against certain bone, connective tissue and brain cancers.

The license agreement grants the spin-out company ADCendo worldwide rights to explore and commercialize certain inventions made by researchers at the Finsen Laboratory related to Antibody Drug Conjugate (ADC) drugs targeting the novel uPARAP receptor. These inventions are based on many years of extensive research on this receptor in cancer as part of the laboratory’s basic research.

ADCendo’s drug candidates (ADCs) are a new class of highly potent biopharmaceutical drugs composed of an antibody linked to a biologically active drug or cytotoxic compound. This allows them to combine targeting capabilities of antibodies with the cell-killing ability of cytotoxic drugs.

“By targeting antigens that are highly expressed in certain cancer tissues and that hold strong ability of being internalized into the cancer cell, we can actively aim for and attack the cancer. This leaves the healthy cells much less affected than treatment with traditional chemotherapy drugs,” explains Henrik Stage, CEO of ADCendo.

Agreement an important step towards a treatment

Published research has documented ADCendo drug candidates’ ability to completely eradicate human cancers in animal models. With the new license agreement in place the company is ready for the next step on the road towards a treatment.

Henrik Stage explains:

“We are excited about the opportunity to further research, develop and commercialize these drug candidates for treatment of some very serious bone, connective tissue and brain cancers for which today there are no treatments available. We will now select the most promising ADC drug candidate and take it through preclinical and clinical development and hope it may end up as a new treatment option with the potential to significantly impact the lives of cancer patients.”

Partners and investors eagerly await development stage

Under the terms of the license agreement, the University of Copenhagen and Capital Region of Denmark are eligible to receive milestone payments upon successful achievement of key development – and registration milestones as well as royalties. Niels Skjærbæk, Senior Executive Advisor at the Tech Transfer Office at University of Copenhagen helped facilitate the licensing agreement.

He says: “A promising spin-out biotech company is always a significant achievement. The ADCendo founders have been very focused and displayed great determination through this process, we are therefore all very excited about this new cancer biotech company, and we will follow the drug development challenges with great interest.”

A number of activities aimed at investigating the use and commercialization of the ADC drugs targeting the uPARAP receptor in cancers are partly funded by a pre-seed grant from Novo Seeds.

Christina Trojel-Hansen, Senior Investment Associate of Novo Seeds comments: ”We are pleased to see the significant progress the scientific founder team has made towards the building a start-up company with the support from the pre-seed funding program. ADCendo’s technology is based on exiting new biological insight and could potentially be developed for severe cancers with a high unmet medical needs”.


About ADCendo ApS

ADCendo ApS is a biotech company researching and developing novel antibody-drug-conjugates (ADCs) against selected serious bone, connective tissue and brain cancers for which there today are no treatments available. The company was founded in 2017 by the scientist inventors, Niels Behrendt, Lars Henning Engelholm and Christoffer Nielsen, from The University of Copenhagen / Rigshospitalet and Henrik Stage, a biotech-entrepreneur active in several biotech companies and previously CEO/CFO of Santaris Pharma which was acquired by Roche in 2014. ADCendo holds the worldwide rights to explore certain inventions made by the founders and patented by the University of Copenhagen and Rigshospitalet as well as results from ongoing research – partly financed through a pre-seed grant from Novo Seeds. Research made by the scientific founders and based on ADCendo’s drug candidates was published in “Oncotarget, Advance Publications 2017”. ADCendo has secured funding for its early preclinical activities related to lead compound selection, pharmacology and preliminary tox studies and will initiate discussions with potential investors regarding the funding needed for scaling up, IND enabling tox and preparation for and making phase 1/2 studies. Further the company will continue discussions with pharma companies to explore potential collaboration opportunities for its projects. For more information: www.adcendo.dk.

ADCs are a new class of highly potent biopharmaceutical drug composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. ADCs combine the unique and very sensitive targeting capabilities of antibodies allowing sensitive discrimination between healthy and cancer tissues with the cell-killing ability of cytotoxic drugs. To date, four ADCs have received market approval and several ADCs are currently in clinical trials.

ADCendo’s first drug candidate is an ADC targeting the uPARAP receptor. This receptor is highly expressed in several bone, connective tissue and brain cancers such as:

• Sarcomas (primary bone cancer and soft tissue tumors with no efficient present treatment if metastasis has occurred)
• Glioblastomas (GBM; the most malignant brain tumors and presently incurable)

The University of Copenhagen / Capital Region of Denmark. The Tech Transfer Office at the University of Copenhagen helps commercialize the excellent research conducted at the University of Copenhagen and the hospitals of the Capital Region of Denmark. The Tech Transfer Offices commercial officers identify research with commercial potential and helps to realize that potential for existing businesses or start-up businesses (spin-outs). The University of Copenhagen is ranked 13th in Reuters’ list of Europe’s Most Innovative Universities (2017).
For more information, visit business.ku.dk/commercialisation

Novo Holdings A/S is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S, Novozymes A/S and NNIT A/S, and is responsible for managing the Foundation’s assets.

In addition to being the major shareholder in the Novo Group companies, Novo Holdings provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within life science and manages a broad portfolio of financial assets.

It is the vision of Novo Holdings to be recognized as a world-leading life science investor with a focus on creating long-term value. Read more at www.novoholdings.dk.

Novo Seeds, the early stage investment arm of Novo Holdings, has two components, a pre-seed grant donation capability and an equity financing capability. Both aims at identifying and developing the unexplored commercial potential that is present in academic research and early stage applied research at universities and biotech companies in the life science area in Scandinavia and across Europe.
The pre-seed grant donation program provides managerial and strategic support to early stage projects based on ideas and results with commercial potential for Scandinavian projects.
The equity financing capability aims at supporting more advanced projects across Europe.
For more information, visit www.novo.dk.

For further information please contact: Henrik Stage, CEO of ADCendo ApS
+45 4026 0900
henrik.stage.dk (at) gmail.com

September 27th, 2017

ADCendo invited to present at Sachs Annual Biotech in Europe Forum in Basel

Copenhagen, Denmark – September 27th, 2017

CEO to present the company under the Rising Star: Start-Up Showcase

Download the presentation powerpoint here:

ADCendo-Sachs-Basel

ADCendo ApS, a biotech company researching and developing novel antibody-drug-conjugates (ADCs) against selected bone, connective tissue and brain cancers, announced that Henrik Stage, Chief Executive Officer of ADCendo, will present the company at the Sachs Annual Biotech in Europe Forum under the Rising Star section.

“We are very proud of being invited to present as a Rising Star at the Sachs Annual Biotech in Europe Forum only 2 months after the company was established. The forum is recognized as one of the leading international stages for those interested in investing and partnering in the biotech industry, and presents a nice opportunity to get in front of some of the leading figures within Europe’s pharmaceutical and biotech industry” Henrik Stage, CEO of ADCendo, comments and continues: “A number of our activities have been partly funded by a pre-seed grant from Novo Seeds. Going forward ADCendo will need additional investments or pharma collaboration for funding the clinical development. The Sachs Biotech Forum is an excellent place to start this process”.


About ADCendo ApS

ADCendo ApS is a biotech company researching and developing novel antibody-drug-conjugates (ADCs) against selected serious bone, connective tissue and brain cancers for which there today are no treatments available. The company was founded in 2017 by the scientist inventors, Niels Behrendt, Lars Henning Engelholm and Christoffer Nielsen, from The University of Copenhagen / Rigshospitalet and Henrik Stage, a biotech-entrepreneur active in several biotech companies and previously CEO/CFO of Santaris Pharma which was acquired by Roche in 2014. ADCendo holds the worldwide rights to explore certain inventions made by the founders and patented by the University of Copenhagen and Rigshospitalet as well as results from ongoing research – partly financed through a pre-seed grant from Novo Seeds. Research made by the scientific founders and based on ADCendo’s drug candidates was published in “Oncotarget, Advance Publications 2017”.

ADCendo has secured funding for its early preclinical activities related to lead compound selection, pharmacology and preliminary tox studies and will initiate discussions with potential investors regarding the funding needed for scaling up, IND enabling tox and preparation for and making phase 1/2 studies. Further the company will continue discussions with pharma companies to explore potential collaboration opportunities for its projects. For more information: www.adcendo.dk.


ADCs
are a new class of highly potent biopharmaceutical drug composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound.

ADCs combine the unique and very sensitive targeting capabilities of antibodies allowing sensitive discrimination between healthy and cancer tissues with the cell-killing ability of cytotoxic drugs.

To date, four ADCs have received market approval and several ADCs are currently in clinical trials. ADCendo’s first drug candidate is an ADC targeting the uPARAP receptor. This receptor is highly expressed in several bone, connective tissue and brain cancers such as:

  • Sarcomas (primary bone cancer and soft tissue tumors with no efficient present treatment if metastasis has occurred)
  • Glioblastomas (GBM; the most malignant brain tumors and presently incurable)

For further information please contact:
Henrik Stage, CEO of ADCendo ApS

+45 4026 0900
henrik.stage.dk (at) gmail.com

September 22nd, 2017

ADCendo founder Christoffer Nielsen takes home runner-up award for best poster at World ADC San Diego 2017.

San Diego, USA, September 22nd, 2017

Presentation of ADCendo’s results and targeting programme was well received by peers in the ADC community at the World ADC congress held in San Diego, USA, September 2017. The initial display of results in a poster format led to an invitation for an oral presentation on the main stage. At the congress award ceremony, ADCendo CTO Christoffer Nielsen was awarded the best poster runner-up prize as the presenter.